Piazza M, Abrescia N, Picciotto L, Cotugno M, Vegnente A, Iorio R, Cimmino L
Clinica delle Malattie Infettive, Università di Napoli.
Boll Soc Ital Biol Sper. 1991 Feb;67(2):207-11.
Following the demonstration of a fully satisfactory immunogenic activity of a hepatitis B vaccination protocol consisting of three doses of Hevac B Pasteur vaccine given at 3,5 and 11 months of age, it was possible to administer this vaccine at the same times as the vaccinations for diphtheria, tetanus and polio which are mandatory in Italy at those ages. We have also shown that both another plasma-derived vaccine, H-B-VAX (MSD), as well as the DNA-recombinant Engerix B (SK&F) are highly immunogenic when given at the same times as the mandatory childhood vaccinations. In this paper we demonstrate that the same schedule can be used for another hepatitis B vaccine prepared by a DNA-recombinant technique, Recombivax HB (MSD) recently introduced in Italy. In fact two doses of this vaccine, the first given at three months of age and the second two months later, resulted in a 100% seroconversion rate and a mean anti-HBs titre of 440 mUI/ml. Although the date are incomplete since the third dose will be given at 11 months of age, we conclude that this hepatitis B vaccine can also be used in the mass vaccination campaigns of infants in Italy, the first of which was initiated in January 1987 in an hyperendemic area near Naples (HBsAg prevalence about 14%). We underline that this mass vaccination campaign is the first in Europe.
在证明了由3剂巴斯德公司的Hevac B疫苗组成的乙肝疫苗接种方案具有完全令人满意的免疫原性后，该疫苗可在意大利这些年龄阶段强制接种的白喉、破伤风和脊髓灰质炎疫苗接种的同时进行接种。我们还表明，另一种血浆源性疫苗H-B-VAX（默克公司）以及重组DNA的安在时（史克必成公司）在与儿童期强制接种疫苗同时接种时具有高度免疫原性。在本文中，我们证明相同的接种程序可用于意大利最近引进的另一种通过重组DNA技术制备的乙肝疫苗——重组酵母乙肝疫苗（默克公司）。事实上，两剂该疫苗，第一剂在3月龄接种，第二剂在两个月后接种，产生了100%的血清转化率，抗-HBs平均滴度为440 mUI/ml。虽然由于第三剂将在11月龄接种，数据不完整，但我们得出结论，这种乙肝疫苗也可用于意大利婴儿的大规模疫苗接种活动，其中第一次大规模疫苗接种活动于1987年1月在那不勒斯附近的一个高流行地区启动（HBsAg流行率约14%）。我们强调，这次大规模疫苗接种活动是欧洲的首次此类活动。
